Xencor (XNCR) Non Operating Investment Income (2015 - 2026)
Xencor's (XNCR) quarterly Non Operating Investment Income came in at -$51.9 million in Q1 2026, down 5618.49% year-on-year from $941000.0 in Q1 2025, and down 201.02% on a QoQ basis from $51.4 million in Q4 2025.
Xencor (XNCR) Non Operating Investment Income (2015 - 2026) Analysis & Trends
Xencor (XNCR) has 12 years of Non Operating Investment Income data on file, last reported at -$51.9 million in Q1 2026.
- On a quarterly basis, Non Operating Investment Income fell 5618.49% year-over-year to -$51.9 million in Q1 2026; TTM through Mar 2026 was $48.6 million, a 248.28% increase from a year earlier, with the FY2025 full-year figure at $101.5 million, up 423.07% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at -$51.9 million, down from $51.4 million in the prior quarter.
- Over the last five years, Non Operating Investment Income for XNCR reached as high as $51.4 million in Q4 2025 and fell as low as -$51.9 million in Q1 2026.
- Historically, Non Operating Investment Income has averaged $3.8 million across 5 years, with a median of $2.3 million in 2024.
- Across the five-year window, Non Operating Investment Income plunged 15008.7% in 2022 and surged 671.17% in 2024, its largest moves.
- Year by year, Non Operating Investment Income stood at $31.8 million in 2022, then sank by 58.37% to $13.2 million in 2023, then slumped by 333.98% to -$31.0 million in 2024, then soared by 265.96% to $51.4 million in 2025, then sank by 201.02% to -$51.9 million in 2026.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were -$51.9 million in Q1 2026, $51.4 million in Q4 2025, and $44.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - | -51.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.93 Mn |
| Mar 31, 2026 | -51.93 Mn |
| Dec 31, 2025 | 51.41 Mn |
| Dec 31, 2025 | 51.41 Mn |
| Sep 30, 2025 | 44.20 Mn |
| Sep 30, 2025 | 44.20 Mn |
| Jun 30, 2025 | 4.97 Mn |
| Jun 30, 2025 | 4.97 Mn |
| Mar 31, 2025 | 941,000.00 |
| Mar 31, 2025 | 941,000.00 |
| Dec 31, 2024 | -30.97 Mn |
| Dec 31, 2024 | -30.97 Mn |
| Sep 30, 2024 | 9.25 Mn |
| Sep 30, 2024 | 9.25 Mn |
| Jun 30, 2024 | -12.03 Mn |
| Jun 30, 2024 | -12.03 Mn |
| Mar 31, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.33 Mn |
| Dec 31, 2023 | 13.24 Mn |
| Dec 31, 2023 | 13.24 Mn |